Reni Benjamin
Stock Analyst at Citizens
(1.37)
# 3,625
Out of 5,147 analysts
162
Total ratings
36.76%
Success rate
-13.63%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.78 | +79.86% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.65 | +76.99% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $5.73 | +109.42% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $74.13 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.28 | +614.03% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.25 | +304.20% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $101.27 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $7.25 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.60 | +566.44% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.81 | +120.99% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.16 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.57 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $15.57 | -35.77% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $20.47 | +12.36% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.21 | +18.76% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.73 | +220.73% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.90 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $16.59 | +141.11% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.86 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.76 | +44.93% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.38 | -14.71% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.47 | +29.12% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.63 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $133.76 | +135.50% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $75.42 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $252.35 | +5.01% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.10 | +314.63% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $9.04 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.99 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $30.09 | -60.12% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.70 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.78
Upside: +79.86%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.65
Upside: +76.99%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $5.73
Upside: +109.42%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $74.13
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.28
Upside: +614.03%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.25
Upside: +304.20%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $101.27
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.25
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.60
Upside: +566.44%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.81
Upside: +120.99%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.16
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.57
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $15.57
Upside: -35.77%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $20.47
Upside: +12.36%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.21
Upside: +18.76%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.73
Upside: +220.73%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.90
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $16.59
Upside: +141.11%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.86
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.76
Upside: +44.93%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.38
Upside: -14.71%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.47
Upside: +29.12%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.63
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $133.76
Upside: +135.50%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $75.42
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $252.35
Upside: +5.01%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.10
Upside: +314.63%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $9.04
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.99
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $30.09
Upside: -60.12%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $21.70
Upside: -